HomeSectors Biotechnology

Biotechnology

Neuren Pharmaceuticals Confirms Daybue Sales Outlook After ASX Aware Letter

Affordable £2.50 Drug Extends Lives of Prostate Cancer Patients

JPMorgan Healthcare Conference 2026 Breaks Ground On Pharma Frontiers

Aged Care Crisis Australia Deepens As Allman-Payne Blasts Health Officials Over System Failures

Could This Common Drug Stop One of Childhood’s Deadliest Cancers?

Popular Hair Loss Medication Hides Dark Secret: Men Face Suicide Risk After Treatment

Medibank’s Bold Vision: Doubling Health Engagement to 10 Million by 2030

Botanix Pharmaceuticals Sofdra Revenue Surges 65% In Q1 FY26

ASX Healthcare Giant Ansell Reports Major Security Breach Through Third-Party Software

Radiopharm Receives Approval To Advance RAD-202 HER2 Trial Dosing

COLITCO LLP accepts no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. COLITCO LLP or an associate may receive a commission for funds raised.

↑

Biotechnology

Recent Posts

Categories

Disclaimer

Categories

Trending Posts